Journal of Gastric Cancer

  • 제24권4호
  • /
  • Pages.353-355
  • /
  • 2024
  • /
  • 2093-582X(pISSN)
  • /
  • 2093-5641(eISSN)
대한위암학회 (The Korean Gastric Cancer Association)
권호 표지
DOI QR코드

DOI QR Code

Reply: Comment on The Necessity of Guidance: Optimizing Adjuvant Therapy for Stage II/III MSI-H Gastric Cancer Through the Interplay of Evidence, Clinical Judgment, and Patient Preferences

  • In-Ho Kim (Division of Medical Oncology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea) ;
  • Wonyoung Choi (Center for Clinical Trials, National Cancer Center) ;
  • Hye Sook Han (Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine) ;
  • The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team (The Development Working Group for the Korean Practice Guidelines for Gastric Cancer 2024 Task Force Team)
  • 투고 : 2024.09.20
  • 심사 : 2024.09.20
  • 발행 : 2024.10.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

키워드

참고문헌

  1. Song GJ, Choi YY. The necessity of guidance: optimizing adjuvant therapy for stage II/III MSI-H gastric cancer through the interplay of evidence, clinical judgment, and patient preferences. J Gastric Cancer 2024;24:243-245.
  2. Kim TH, Kim IH, Kang SJ, Choi M, Kim BH, Eom BW, et al. Korean practice guidelines for gastric cancer 2022: an evidence-based, multidisciplinary approach. J Gastric Cancer 2023;23:3-106.
  3. National Comprehensive Cancer Network (NCCN). National Comprehensive Cancer Network Guidelines in Oncology. Gastric Cancer. Version 4.2024 [Internet]. Plymouth Meeting (PA): NCCN; 2024 [cited 2024 Sep 11]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
  4. European Society of Medical Oncology (ESMO). ESMO Gastric Cancer Living Guideline, v1.3 June 2024 [Internet]. Lugano: ESMO; 2024 [cited 2024 Sep 11]. Available from: https://www.esmo.org/living-guidelines/esmo-gastric-cancer-living-guideline.
  5. Wang FH, Zhang XT, Tang L, Wu Q, Cai MY, Li YF, et al. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond) 2024;44:127-172.
  6. Choi YY, Bae JM, An JY, Kwon IG, Cho I, Shin HB, et al. Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J Surg Oncol 2014;110:129-135.
  7. An JY, Kim H, Cheong JH, Hyung WJ, Kim H, Noh SH. Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. Int J Cancer 2012;131:505-511.
  8. Kim SY, Choi YY, An JY, Shin HB, Jo A, Choi H, et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: results from a large cohort with subgroup analyses. Int J Cancer 2015;137:819-825.
  9. Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J Clin Oncol 2019;37:3392-3400.
  10. Petrelli F, Antista M, Marra F, Cribiu' FM, Rampulla V, Pietrantonio F, et al. Adjuvant and neoadjuvant chemotherapy for MSI early gastric cancer: a systematic review and meta-analysis. Ther Adv Med Oncol 2024;16:17588359241231259.
  11. Nie RC, Chen GM, Yuan SQ, Kim JW, Zhou J, Nie M, et al. Adjuvant chemotherapy for gastric cancer patients with mismatch repair deficiency or microsatellite instability: systematic review and meta-analysis. Ann Surg Oncol 2022;29:2324-2331.
  12. Kim JW, Cho SY, Chae J, Kim JW, Kim TY, Lee KW, et al. Adjuvant chemotherapy in microsatellite instability-high gastric cancer. Cancer Res Treat 2020;52:1178-1187.
  13. Andre T, Tougeron D, Piessen G, de la Fouchardiere C, Louvet C, Adenis A, et al. Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: the GERCOR NEONIPIGA phase II study. J Clin Oncol 2023;41:255-265.
  14. Lorenzen S, Gotze TO, Thuss-Patience P, Biebl M, Homann N, Schenk M, et al. Perioperative atezolizumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable esophagogastric cancer: interim results from the randomized, multicenter, phase II/III DANTE/IKF-s633 trial. J Clin Oncol 2024;42:410-420.
  15. Shitara K, Rha SY, Wyrwicz LS, Oshima T, Karaseva N, Osipov M, et al. Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study. Lancet Oncol 2024;25:212-224.
  16. AstraZeneca. Imfinzi plus chemotherapy significantly improved pathologic complete response in gastric and gastroesophageal junction cancers in MATTERHORN Phase III trial [Internet]. Cambridge: AstraZeneca; 2023 [cited 2024 Sep 11]. Available from: https://www.astrazeneca.com/media-centre/press-releases/2023/imfinzi-plus-chemotherapy-significantly-improved-pathologic-complete-response-in-gastric-and-gastroesophageal-junction-cancers-in-matterhorn-phase-iii-trial.html.
  17. Kang YK, Terashima M, Kim YW, Boku N, Chung HC, Chen JS, et al. Adjuvant nivolumab plus chemotherapy versus placebo plus chemotherapy for stage III gastric or gastro-oesophageal junction cancer after gastrectomy with D2 or more extensive lymph-node dissection (ATTRACTION-5): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol 2024;9:705-717.